^
Association details:
Biomarker:MYC rearrangement + BCL6 rearrangement
Cancer:Diffuse Large B Cell Lymphoma
Regimen:C-RICE (carboplatin + carfilzomib + etoposide IV + ifosfamide + Rituxan (rituximab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

370 | A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C-RICE) IN TRANSPLANT-ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Published date:
06/09/2021
Excerpt:
MYC and BCL2/BCL6 rearrangements were noted in 3 pts, an additional 2 pts had an isolated MYC rearrangement. Best ORR was 62% (45% CR, 15% PR), 52% pts underwent HDC-ASCT....ORR of 100% was observed in pts with non-GCB DLBCL...C-RICE is well tolerated in pts with R/R DLBCL...